No Picture
News

Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

– NIAID to Study Use of ENHANZE® Technology with Broadly Neutralizing Antibodies for Development of New HIV Treatments –

SAN DIEGO, June 25, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and D… […]

No Picture
News

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)

LA JOLLA, Calif., June 25, 2019 /PRNewswire/ — EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive r… […]

No Picture
News

Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

– Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU-838; Top-line Data Anticipated in Q3 2020 –

SAN DIEGO, June 21, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmac… […]

No Picture
News

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test

Reimbursement Decision Follows IQWiG’s Recommendation Based on TAILORx Study Results

REDWOOD CITY, Calif., June 20, 2019 /PRNewswire/ — Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement dec… […]

No Picture
News

Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

Conference call scheduled for today at 9:30 a.m. EDT

SAN DIEGO and VANCOUVER, British Columbia, June 19, 2019 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a … […]

No Picture
News

Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York

MARINA DEL REY, Calif., June 18, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today anno… […]

No Picture
News

Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting

SAN DIEGO, June 13, 2019 /PRNewswire/ — Qpex Biopharma today announced that preclinical data on its investigational beta-lactamase inhibitor QPX7728 will be featured in several presentations at the 2019 ASM Microbe Meeting to be held June 20-24 in… […]